Design Therapeutics, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 68/100
What the filing says
Design Therapeutics has registered shares with an aggregate offering price of up to $200,000,000 under an Open Market Sale Agreement (OMSA) dated April 27, 2022 with Jefferies LLC. The registration statement (File No. 333-287043) and prospectus supplement dated November 4, 2026 permit sale of up to 25,000,000 shares of common stock at market prices. This is a shelf registration enabling future capital raises without additional SEC filings.
Why this rating
At-the-market offering up to $200M represents 175% of current market cap—material if fully deployed. However, OMSA is discretionary (no obligation to sell), and proceeds are contingent on future market conditions. Dilution risk is real but timing and amount remain uncertain.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.